Switching patients with schizophrenia from paliperidone palmitate to aripiprazole lauroxil: A 6-month, prospective, open-label study

Brian J. Miller; Amy Claxton; Yangchun Du; Peter J. Weiden; Steven G. Potkin

doi:10.1016/j.schres.2019.01.038

Switching patients with schizophrenia from paliperidone palmitate to aripiprazole lauroxil: A 6-month, prospective, open-label study

Brian J. Miller, Amy Claxton, Yangchun Du, Peter J. Weiden, Steven G. Potkin

Psychiatry and Health Behavior

Research output: Contribution to journal › Article › peer-review

6 Scopus citations

Abstract

We assessed the effectiveness of switching from paliperidone palmitate (PP) or risperidone long-acting injection (RLAI) to aripiprazole lauroxil (AL). Prospective, 6-month study in patients with schizophrenia with residual symptoms or intolerance with PP/RLAI. Effectiveness assessed via all-cause and medication-related discontinuation; CGI-S/BPRS and adverse event monitoring assessed efficacy/tolerability, respectively. Fifty-one patients (n = 50 PP; n = 1 RLAI) enrolled; 35 completed the study. All-cause and medication-related discontinuation was 30% and 9% over 6 months, respectively. CGI-S/BPRS improved significantly in those continuing treatment. Adverse events were generally mild to moderate. Patients with efficacy or tolerability concerns with PP/RLAI can be switched to AL.

Original language	English (US)
Pages (from-to)	44-48
Number of pages	5
Journal	Schizophrenia Research
Volume	208
DOIs	https://doi.org/10.1016/j.schres.2019.01.038
State	Published - Jun 2019

Keywords

Antipsychotic
Aripiprazole lauroxil
Long-acting injection
Paliperidone palmitate
Schizophrenia
Switching

ASJC Scopus subject areas

Psychiatry and Mental health
Biological Psychiatry

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.schres.2019.01.038

Cite this

@article{a2b4301f929d497b9290a30626307c19,

title = "Switching patients with schizophrenia from paliperidone palmitate to aripiprazole lauroxil: A 6-month, prospective, open-label study",

abstract = "We assessed the effectiveness of switching from paliperidone palmitate (PP) or risperidone long-acting injection (RLAI) to aripiprazole lauroxil (AL). Prospective, 6-month study in patients with schizophrenia with residual symptoms or intolerance with PP/RLAI. Effectiveness assessed via all-cause and medication-related discontinuation; CGI-S/BPRS and adverse event monitoring assessed efficacy/tolerability, respectively. Fifty-one patients (n = 50 PP; n = 1 RLAI) enrolled; 35 completed the study. All-cause and medication-related discontinuation was 30% and 9% over 6 months, respectively. CGI-S/BPRS improved significantly in those continuing treatment. Adverse events were generally mild to moderate. Patients with efficacy or tolerability concerns with PP/RLAI can be switched to AL.",

keywords = "Antipsychotic, Aripiprazole lauroxil, Long-acting injection, Paliperidone palmitate, Schizophrenia, Switching",

author = "Miller, {Brian J.} and Amy Claxton and Yangchun Du and Weiden, {Peter J.} and Potkin, {Steven G.}",

note = "Publisher Copyright: {\textcopyright} 2019 The Authors",

year = "2019",

month = jun,

doi = "10.1016/j.schres.2019.01.038",

language = "English (US)",

volume = "208",

pages = "44--48",

journal = "Schizophrenia Research",

issn = "0920-9964",

publisher = "Elsevier",

}

TY - JOUR

T1 - Switching patients with schizophrenia from paliperidone palmitate to aripiprazole lauroxil

T2 - A 6-month, prospective, open-label study

AU - Miller, Brian J.

AU - Claxton, Amy

AU - Du, Yangchun

AU - Weiden, Peter J.

AU - Potkin, Steven G.

PY - 2019/6

Y1 - 2019/6

N2 - We assessed the effectiveness of switching from paliperidone palmitate (PP) or risperidone long-acting injection (RLAI) to aripiprazole lauroxil (AL). Prospective, 6-month study in patients with schizophrenia with residual symptoms or intolerance with PP/RLAI. Effectiveness assessed via all-cause and medication-related discontinuation; CGI-S/BPRS and adverse event monitoring assessed efficacy/tolerability, respectively. Fifty-one patients (n = 50 PP; n = 1 RLAI) enrolled; 35 completed the study. All-cause and medication-related discontinuation was 30% and 9% over 6 months, respectively. CGI-S/BPRS improved significantly in those continuing treatment. Adverse events were generally mild to moderate. Patients with efficacy or tolerability concerns with PP/RLAI can be switched to AL.

AB - We assessed the effectiveness of switching from paliperidone palmitate (PP) or risperidone long-acting injection (RLAI) to aripiprazole lauroxil (AL). Prospective, 6-month study in patients with schizophrenia with residual symptoms or intolerance with PP/RLAI. Effectiveness assessed via all-cause and medication-related discontinuation; CGI-S/BPRS and adverse event monitoring assessed efficacy/tolerability, respectively. Fifty-one patients (n = 50 PP; n = 1 RLAI) enrolled; 35 completed the study. All-cause and medication-related discontinuation was 30% and 9% over 6 months, respectively. CGI-S/BPRS improved significantly in those continuing treatment. Adverse events were generally mild to moderate. Patients with efficacy or tolerability concerns with PP/RLAI can be switched to AL.

KW - Antipsychotic

KW - Aripiprazole lauroxil

KW - Long-acting injection

KW - Paliperidone palmitate

KW - Schizophrenia

KW - Switching

UR - http://www.scopus.com/inward/record.url?scp=85061096805&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85061096805&partnerID=8YFLogxK

U2 - 10.1016/j.schres.2019.01.038

DO - 10.1016/j.schres.2019.01.038

M3 - Article

C2 - 30745067

AN - SCOPUS:85061096805

SN - 0920-9964

VL - 208

SP - 44

EP - 48

JO - Schizophrenia Research

JF - Schizophrenia Research

ER -

Switching patients with schizophrenia from paliperidone palmitate to aripiprazole lauroxil: A 6-month, prospective, open-label study

Abstract

Keywords

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this